Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

PL EN


Preferences help
enabled [disable] Abstract
Number of results
2009 | 50 | 4 | 399-403

Article title

A vitamin K epoxide reductase-oxidase complex gene polymorphism (?1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists

Title variants

Languages of publication

EN

Abstracts

EN
A daily dose of vitamin K antagonists (VKAs) may vary and its range depends on various interrelated factors. Low responsiveness to VKA (defined as a failure to achieve a target international normalized ratio [INR]) is associated with polymorphisms of the vitamin K epoxide reductase-oxidase complex gene (VKORC1). A highly prevalent promoter single-nucleotide polymorphism (VKORC1-1639 G>A, rs17878363) impairs VKORC1 expression and determines the interindividual variability of the target INR. We studied 57 patients receiving oral anticoagulation, including 50 subjects treated with acenocoumarol (mean dose: 5.7+-2.3 mg/day) and 7 treated with warfarin (mean dose: 9.6+-4.2 mg/day). The indications for the use of oral anticoagulant therapy were as follows: deep-vein thrombosis (N = 23); pulmonary embolism (N = 20); arterial thrombosis (N = 5); stroke (N = 4); atrial fibrillation with transient ischemic attacks (N = 2), and history of multiple thromboembolic events (N = 3). Identification of the VKORC1 genomic variation was performed using DNA sequencing methods. The prevalence of the mutated allele (VKORC1 -1639A) was 41%. The VKORC1 -1639G allele carriers required a higher daily dose of acenocoumarol (5.9+-1.9 mg) than the noncarriers (4.1+-3.3 mg; P < 0.001). All of 5 low responders (who failed to achieve a target INR using standard dose requirements of VKAs) were homozygous for the 1639G allele. Low responders did not differ from good responders with respect to age, gender, and body mass index. Our findings suggest the potential benefits from pharmacogenetic testing, and provide evidence that the VKORC1 -1639 G>A gene polymorphism may explain at least in part the low responsiveness to acenocoumarol.

Discipline

Year

Volume

50

Issue

4

Pages

399-403

Physical description

Contributors

author
author
author
author

References

Document Type

ARTICLE

Publication order reference

E. Stepien, John Paul II Hospital, Pradnicka 80, 31?202 Krakow, Poland

Identifiers

YADDA identifier

bwmeta1.element.element-from-psjc-07ab6af1-6eb3-3043-82bf-c0a0dce970db
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.